 <h1>Sogroya Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>somapacitan-beco</i></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about somapacitan-beco. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Sogroya.</p><p><i>Applies to somapacitan-beco: subcutaneous solution</i></p><h3>Metabolic</h3><p>Elevated phosphate and creatine phosphokinase occurred intermittently and were non-progressive.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Elevated phosphate (17.5%) </p><p><b>Common</b> (1% to 10%): Elevated creatine phosphokinase, blood creatinine kinase increase, weight increased</p><p><b>Frequency not reported</b>: Glucose intolerance, diabetes mellitus, fluid retention<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Sleep disorder, dizziness</p><p><b>Frequency not reported</b>: Intracranial hypertension<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Adrenal insufficiency, hypoadrenalism, hypothyroidism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Dyspepsia, vomiting</p><p><b>Frequency not reported</b>: Pancreatitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Severe hypersensitivity<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (10%)</p><p><b>Common</b> (1% to 10%): Arthralgia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Frequency not reported</b>: Neoplasms<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Peripheral edema</p><p><b>Frequency not reported</b>: Increased mortality in patients with acute critical illness<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Lipohypertrophy, lipoatrophy<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Tonsillitis<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Sogroya (somapacitan)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><h2>More about Sogroya (somapacitan-beco)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: growth hormones</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Sogroya &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Adult Human Growth Hormone Deficiency</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>